Introduction And Objectives: Several interventions can improve low-density lipoprotein cholesterol (LDL-C) control. Our main objective was to evaluate the efficacy of a combined intervention to improve LDL-C control in patients with hypercholesterolemia. The study also assessed the efficacy of the intervention in improving adherence (pharmacological, diet, and exercise).

Methods: A multicenter, parallel group, randomized clinical trial (primary care) was conducted in 358 adults diagnosed with hypercholesterolemia, whether receiving prior drug therapy or not. We compared 178 participants who received the combined intervention (written material, self-completed registration cards, and messages to mobile telephones) with 178 controls. The main outcome variable was the proportion of participants with adequate LDL-C control (target levels of the European guidelines on dyslipidemia and cardiovascular risk) at 24 months.

Results: At 24 months, the mean reduction in LDL-C was significantly higher in the intervention group (23.8mg/dL [95%CI, 17.5-30.1]) than in the control group (14.6mg/dL [95%CI, 8.9-20.4]; P=.034). The mean LDL-C decrease was 13.1%±28.6%. At 1 year, the proportion of participants with adequate control was significantly higher in the intervention group than in the control group (43.7% vs 30.1%; P=.011; RR, 1.46). Adherence was significantly higher in the intervention group, both to drug therapy (77.2% vs 64.1%; P=.029) and exercise (64.9% vs 35.8; P<.001), but not to diet.

Conclusions: The combined intervention significantly reduced LDL-C (by more than 13% at 2 years) and improved the degree of LDL-C control in patients with hypercholesterolemia at 1 year.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rec.2017.05.029DOI Listing

Publication Analysis

Top Keywords

ldl-c control
12
higher intervention
12
intervention group
12
efficacy combined
8
improve low-density
8
low-density lipoprotein
8
lipoprotein cholesterol
8
control patients
8
patients hypercholesterolemia
8
randomized clinical
8

Similar Publications

This study evaluated the management of dyslipidemia in Turkey with the goal of understanding current diagnosis and treatment patterns, as well as identifying unmet needs in achieving effective low-density lipoprotein cholesterol (LDL-C) targets. Using a Delphi panel consisting of nine expert cardiologists, the study reveals key gaps in dyslipidemia management, particularly in the underutilization of combination therapies, such as statins and PCSK9 inhibitors, which are crucial for achieving LDL-C targets in high-risk patients. The findings indicate that while many patients with very high cardiovascular risk are diagnosed, a significant proportion do not receive optimal treatment to reach LDL-C levels recommended by European guidelines.

View Article and Find Full Text PDF

Predictive value of system immune-inflammation index for the severity of coronary stenosis in patients with coronary heart disease and diabetes mellitus.

Sci Rep

December 2024

Department of Endocrinology, The First Clinical Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.

Coronary heart disease (CHD) has been recognized as a chronic progressive inflammatory disorder, and Diabetes mellitus (DM) is an independent risk factor for the pathogenesis of CHD. Recent research has underscored the systemic immune-inflammation index (SII) as a potent prognostic indicator for individuals suffering from acute coronary syndrome (ACS). This study aimed to delve into the relationship between SII and the degree of coronary atherosclerotic stenosis in non-acute myocardial infarction patients with or without DM.

View Article and Find Full Text PDF

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, significantly influenced by modifiable risk factors, particularly hypercholesterolemia. Despite the availability of effective lipid-lowering drugs, achieving the low-density lipoprotein cholesterol (LDL-C) target levels remains a significant challenge in clinical practice, contributing to persistent high rates of cardiovascular events. The intEgrated multidiscipliNary pathway for large-scale maNagement of dyslipidemiA in high-risk patients (ENNA) Project was designed to address the alarming rates of suboptimal lipid management among high and very-high risk patients in the Province of Enna, Sicily.

View Article and Find Full Text PDF

Background: The prevalence of hypertension among the Tibetan population in Tibet is higher than in other regions of China, and there is a lack of unified epidemiological surveys. This study aims to conduct a standardized epidemiological investigation to assess the current status of hypertension among the Tibetan population, as well as to explore the dose-response relationship between cholesterol (TC), triglyceride glucose index (TyG), triglyceride glucose-body mass index (TyG-BMI), and hypertension in this population.

Methods: From June 2020 to July 2023, a total of 5042 Tibetans aged 18 to 80 years from three cities and one region in Tibet were randomly sampled for the study.

View Article and Find Full Text PDF

miR-432-5p Targeting SORT1 to Protect Artery Smooth Muscle Cells and Inhibit Coronary Artery Disease.

Biochem Genet

December 2024

Department of Cardiovascular Medicine, Shanghai Baoshan Luodian Hospital, No. 88, Yongshun Road, Baoshan District, Shanghai, 201908, China.

Recent studies highlight the crucial role of microRNAs (miRNAs) in coronary artery disease (CAD). This retrospective study investigated the abundance of miR-432-5p in the serum of CAD patients and explored its role. 252 volunteers were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!